JAK inhibitors are a versatile novel drug class that will play a role in different dermatological indications because they block numerous cytokines that play a key role in the pathogenesis of different dermatologic conditions.
"The therapeutic tools of a dermatologist moved from less targeted therapies such as corticosteroids to more target therapies such as TNF-α blockers or cytokine blockers," explained Prof. Brett King (Yale School of Medicine, USA) . The Janus kinase (JAK) family is composed of 4 members: JAK 1,2,3, and tyrosine kinase 2 (TYK2). They play a key role in growth, development, and differentiation . More than 50 cytokines use the JAK-signal transducer and activator of transcription (STAT) pathway. JAK-STAT pathways are involved in signal transduction of many cytokines such as interferon-gamma (IFNγ), IFN-α, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, IL-5, IL-6, IL-12, IL-13, and IL-23 .
JAK-inhibitors are currently registered...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Plaque psoriasis – Efficacy of guselkumab Next Article
Novel anti-IgE drug enables durable urticaria control »